Treatment of Pertussis

First-Line Treatment Options

• The Centers for Disease Control and Prevention recommends azithromycin as the first-line agent for treatment of pertussis in infants < 1 month of age, due to its effectiveness and better tolerability compared to other macrolides 1, 2
• The American Academy of Pediatrics recommends azithromycin and clarithromycin as first-line agents for treatment of pertussis in infants 1-5 months of age, based on in vitro effectiveness, safety, and convenient dosing 1
• For infants ≥ 6 months and children, the Centers for Disease Control and Prevention recommends azithromycin, with a dosing regimen of 10 mg/kg (maximum: 500 mg) on day 1, followed by 5 mg/kg per day (maximum: 250 mg) on days 2-5 1, 3
• For adults, the Centers for Disease Control and Prevention recommends azithromycin, with a dosing regimen of 500 mg on day 1, followed by 250 mg per day on days 2-5 1, 3

Comparative Efficacy and Tolerability

• Azithromycin and clarithromycin are as effective as erythromycin for treatment of pertussis, according to the Centers for Disease Control and Prevention 4

Alternative Treatment Option

• For patients aged >2 months with macrolide contraindications, the Centers for Disease Control and Prevention recommends trimethoprim-sulfamethoxazole (TMP-SMZ) as an alternative agent 4, 5

Treatment Timing and Effectiveness

• Antibiotics administered early in the course of illness can reduce duration and severity of symptoms and lessen the period of communicability, according to the Centers for Disease Control and Prevention 6, 7
• Approximately 80-90% of patients with untreated pertussis will spontaneously clear B. pertussis from the nasopharynx within 3-4 weeks from onset of cough, as reported by the Centers for Disease Control and Prevention 7

Important Considerations and Precautions

• Macrolides are contraindicated in patients with history of hypersensitivity to any macrolide agent, according to the Centers for Disease Control and Prevention 1, 3
• Azithromycin should not be taken with aluminum- or magnesium-containing antacids as they reduce absorption, as recommended by the Centers for Disease Control and Prevention 1, 2

Postexposure Prophylaxis

• The same antimicrobial agents and dosing regimens used for treatment are recommended for postexposure prophylaxis, according to the Centers for Disease Control and Prevention 5, 6
• Prophylaxis should be administered to close contacts, especially in exposure settings that include infants <12 months or women in the third trimester of pregnancy, as recommended by the Centers for Disease Control and Prevention 5, 7

Azithromycin Dosing for Pediatric Pertussis Treatment

Age-Specific Dosing Recommendations

• The Centers for Disease Control and Prevention recommends azithromycin 10 mg/kg/day (maximum 500 mg) on day 1, followed by 5 mg/kg/day (maximum 250 mg) on days 2-5 for children ≥6 months, and 10 mg/kg/day for 5 days for infants <6 months 8, 9, 10
• For infants <6 months, azithromycin 10 mg/kg per day for 5 days is recommended 11, 12
• Azithromycin is preferred over erythromycin due to significantly lower risk of infantile hypertrophic pyloric stenosis (IHPS) in infants <6 months 12

Important Administration Considerations

• Azithromycin should not be administered simultaneously with aluminum- or magnesium-containing antacids as they reduce absorption 11
• Use with caution in patients with impaired hepatic function 11
• Monitor for potential drug interactions with agents metabolized by cytochrome P450 enzyme system (e.g., digoxin, triazolam, ergot alkaloids) 11

Safety Advantages

• Azithromycin has a significantly lower risk of infantile hypertrophic pyloric stenosis (IHPS) compared to erythromycin in infants <1 month 12

Pertussis Treatment Guidelines

Introduction to Pertussis Treatment

• The American Thoracic Society recommends starting antibiotics immediately upon clinical suspicion of pertussis, without waiting for culture confirmation, as early treatment rapidly clears B. pertussis from the nasopharynx and decreases coughing paroxysms 13, 14
• The Centers for Disease Control and Prevention suggest that early treatment (catarrhal phase, first 2 weeks) is critical for effectiveness, while late treatment (paroxysmal phase, >3 weeks) has limited clinical benefit but is still indicated to prevent transmission 13, 14

Antibiotic Therapy

• The American Academy of Pediatrics recommends isolating patients at home and away from work/school for 5 days after starting antibiotics to prevent transmission 13, 14
• The Infectious Diseases Society of America states that therapies such as long-acting β-agonists, antihistamines, corticosteroids, and pertussis immunoglobulin have no significant benefit in controlling coughing paroxysms 13, 14

Medication Considerations

• Erythromycin is associated with infantile hypertrophic pyloric stenosis (IHPS) in infants <1 month, and its use should be avoided if possible; if erythromycin must be used, the recommended dose is 40-50 mg/kg/day in children and 1-2 g per day in adults for 14 days 13, 14
• The American College of Chest Physicians notes that erythromycin resistance is rare (<1%) 13, 14

Treatment of Suspected Pertussis in Infants

Antibiotic Therapy and Infection Control

• The American College of Chest Physicians recommends avoiding erythromycin in infants under 6 months due to the association with infantile hypertrophic pyloric stenosis (IHPS), and instead using alternative macrolides, with a strength of evidence based on clinical trials and observational studies 15
• Early treatment during the catarrhal phase (first 2 weeks) rapidly clears B. pertussis from the nasopharynx and decreases coughing paroxysms and complications, with a high level of evidence from clinical studies 15, 16
• Isolate the infant at home for 5 days after starting antibiotics to prevent spread to other vulnerable individuals, with a strong recommendation based on epidemiological data 15, 17

Diagnostic Confirmation and Vaccination

• Obtain a nasopharyngeal aspirate or Dacron swab for culture to confirm B. pertussis, as isolation of the bacteria is the only certain way to make the diagnosis, with a high level of evidence from microbiological studies 16
• Verify and update the infant's vaccination status and ensure all household contacts are up to date with pertussis vaccination, as vaccine immunity wanes after 5-10 years, with a strong recommendation based on immunological data 17

Supportive Care and Monitoring

• Do not use β-agonists, antihistamines, corticosteroids, or pertussis immunoglobulin, as these have no proven benefit in controlling coughing paroxysms, with a moderate level of evidence from clinical trials 15, 17

Tratamiento Antibiótico para B. Pertussis

Opciones de Tratamiento

• La azitromicina es el agente preferido en lactantes <1 mes debido a su mejor perfil de seguridad, específicamente por el riesgo significativamente menor de estenosis pilórica hipertrófica infantil (IHPS) comparado con eritromicina, según el MMWR Recommendations and Reports 18
• La eritromicina y claritromicina no están recomendadas en lactantes <1 mes por la asociación con IHPS, según el MMWR Recommendations and Reports 18

Agente Alternativo

• El Trimetoprim-Sulfametoxazol (TMP-SMZ) es indicado para pacientes >2 meses con contraindicaciones a macrólidos, según el MMWR Recommendations and Reports 18

Momento Óptimo del Tratamiento

• El tratamiento temprano es crítico, los antibióticos administrados durante la fase catarral eliminan rápidamente B. pertussis de la nasofaringe, disminuyen los paroxismos de tos y reducen las complicaciones, según Chest 19
• No esperar confirmación diagnóstica, iniciar tratamiento inmediatamente ante sospecha clínica, según Chest 19

Consideraciones Importantes y Precauciones

• La eritromicina y claritromicina (pero NO azitromicina) son inhibidores del sistema enzimático citocromo P450 y pueden interactuar con otros fármacos metabolizados por este sistema, según el MMWR Recommendations and Reports 18
• Aislar al paciente en casa y alejado del trabajo/escuela por 5 días después de iniciar antibióticos para prevenir transmisión, según Chest 19

Profilaxis Post-Exposición

• Los mismos regímenes antibióticos y dosis utilizados para tratamiento se recomiendan para profilaxis post-exposición, según el MMWR Recommendations and Reports 18
• Priorizar profilaxis en todos los contactos domiciliarios, lactantes <12 meses, y mujeres en el tercer trimestre del embarazo, según el MMWR Recommendations and Reports 18

Ventajas Comparativas de Azitromicina vs Eritromicina

• La azitromicina tiene igual eficacia que eritromicina para el tratamiento de pertussis, según el MMWR Recommendations and Reports 18
• La azitromicina tiene mejor tolerabilidad con efectos secundarios más leves y menos frecuentes, según el MMWR Recommendations and Reports 18
• La resistencia a eritromicina es rara (<1%), según Chest 19

Treatment of Pertussis with Azithromycin

Historical Context and Treatment Duration

• The Centers for Disease Control and Prevention recommends a 14-day erythromycin regimen due to reported relapses after 7-10 day courses, highlighting the importance of adequate treatment duration 20

Pharmacokinetics and Efficacy of Azithromycin

• Modern macrolides like azithromycin have superior pharmacokinetics with longer tissue half-lives, which supports the use of shorter treatment courses compared to erythromycin 20

Management of Pertussis

Diagnosis and Treatment

• The American Thoracic Society recommends obtaining nasopharyngeal aspirate or Dacron swab for culture to confirm diagnosis, as culture is the only certain way to make the diagnosis, and isolation of bacteria is definitive 21
• Early treatment with antibiotics, such as azithromycin, rapidly clears B. pertussis from the nasopharynx, decreases coughing paroxysms, and reduces complications, with the most effective period for clinical benefit being the first 2 weeks after cough onset 21
• The Centers for Disease Control and Prevention recommends that all children should receive DTaP primary vaccination series with booster in early adolescence, and a single dose Tdap is recommended for adolescents 11-18 years and adults 19-64 years 22

Prevention and Control

• The Centers for Disease Control and Prevention recommends that pregnant women should receive Tdap between 27-36 weeks' gestation with each pregnancy to convey immunity to the newborn, and notes that vaccine immunity wanes after 5-10 years, making previously vaccinated individuals susceptible to infection 22
• Isolate patients at home and away from work/school for 5 days after starting antibiotics, as pertussis is highly contagious with a secondary attack rate exceeding 80% among susceptible persons 21
• The Centers for Disease Control and Prevention recommends administering the same antibiotic regimens used for treatment to close contacts within 21 days of exposure, especially for infants <12 months, pregnant women in third trimester, and healthcare workers with known exposure 22

Management of Culture-Confirmed Bordetella Pertussis

Drug Interaction Considerations

• The American Thoracic Society recommends obtaining a baseline ECG to exclude QTc prolongation before initiating azithromycin in patients taking citalopram, due to the potential for QTc prolongation when combined with macrolides 23
• Azithromycin can be safely initiated if the baseline QTc is normal, with repeat ECG at 1 month to monitor for interval prolongation, as recommended by the Thorax journal 23

Azithromycin Use in Infants Under 6 Months

Introduction to Azithromycin Recommendations

• The Centers for Disease Control and Prevention (CDC) recommends azithromycin as the preferred first-line agent for pertussis in infants <1 month and as a first-line option for infants 1-5 months 24

FDA Licensure Status and Clinical Reality

• The FDA has not licensed any macrolide for use in infants aged <6 months, but the CDC guidelines explicitly recommend azithromycin for pertussis treatment and prophylaxis in this age group 24

Why Azithromycin is Preferred Over Other Macrolides in Young Infants

• Azithromycin has a significantly lower risk of infantile hypertrophic pyloric stenosis (IHPS) compared to erythromycin 24
• Erythromycin is strongly associated with IHPS in infants <1 month and should be avoided 24

Evidence Supporting Safety in Young Infants

• Limited data from clinical studies in infants 1-5 months suggest similar microbiologic effectiveness against pertussis as in older children 24
• The risk of acquiring severe pertussis and life-threatening complications in infants <1 month outweighs the potential risk of IHPS 24

Important Administration Considerations

• Azithromycin does NOT inhibit cytochrome P450 enzymes, unlike erythromycin and clarithromycin 24

When Azithromycin is Most Strongly Indicated in Infants <6 Months

• Infants <12 months, especially <4 months, have the highest risk of severe and fatal pertussis complications 24

Common Pitfalls to Avoid

• The CDC explicitly recommends azithromycin use in infants <6 months with pertussis, despite the lack of FDA licensure 24

CDC Recommendations for Pertussis Antibiotic Management

First‑Line Antibiotic Treatment

• Azithromycin is the preferred first‑line macrolide for all age groups because it offers superior tolerability and a shorter treatment course than erythromycin (strong recommendation)【25】.
• Neonates (< 1 month): Azithromycin 10 mg/kg/day for 5 days is strongly preferred; erythromycin should be avoided due to a 5‑10 % absolute risk of infantile hypertrophic pyloric stenosis (IHPS)【25】.
• All infants receiving any macrolide should be monitored for IHPS symptoms (non‑bilious vomiting, feeding‑related irritability)【25】.
• Infants 1‑5 months: Azithromycin 10 mg/kg/day for 5 days (first‑line) or clarithromycin 15‑20 mg/kg/day divided twice daily for 7 days (alternative); both agents have comparable microbiologic efficacy【25】.
• Children ≥ 6 months and adolescents: Azithromycin 10 mg/kg (max 500 mg) on day 1, then 5 mg/kg/day (max 250 mg) on days 2‑5; clarithromycin 15‑20 mg/kg/day divided twice daily for 7 days (max 1 g/day)【25】.
• Adults: Azithromycin 500 mg on day 1, then 250 mg daily on days 2‑5; clarithromycin 500 mg twice daily for 7 days【25】.

Alternative Therapy for Macrolide‑Intolerant Patients

• Trimethoprim‑sulfamethoxazole (TMP‑SMZ) for 14 days is recommended for patients > 2 months who cannot receive macrolides (adults: double‑strength tablet BID; children: weight‑based dosing)【26】【25】.
• TMP‑SMZ is contraindicated in pregnant women at term, nursing mothers, and infants < 2 months【26】.

Timing and Effectiveness of Treatment

• During the catarrhal phase (first ≈ 2 weeks), antibiotics rapidly eradicate Bordetella pertussis from the nasopharynx【25】 and reduce coughing paroxysms by roughly 50 % (clinical observation).
• In the paroxysmal phase (> 3 weeks from cough onset), clinical benefit to the patient is minimal, but treatment remains essential to eliminate the organism and prevent transmission【25】.
• 80‑90 % of untreated patients spontaneously clear the bacteria within 3‑4 weeks【25】.

Post‑Exposure Prophylaxis

• Prophylaxis uses the same antimicrobial agents and dosing regimens as treatment【26】【25】.
• Priority groups (administer within 21 days of exposure):
  
  • All household and close contacts, regardless of vaccination status.
  • Infants < 12 months (especially < 4 months) – highest risk of severe/fatal disease【25】.
  • Pregnant women in the third trimester【25】.
  • Healthcare workers with documented exposure【26】.
  • Child‑care workers who have contact with infants【26】.
• Asymptomatic contacts with direct exposure to respiratory secretions during catarrhal or paroxysmal stages should receive prophylaxis【26】; coughing household contacts should be treated as confirmed cases, not given prophylaxis【25】.

Special Considerations for Pregnant and Breastfeeding Women

• Azithromycin is the preferred agent for both treatment and prophylaxis in pregnant and lactating women (adult dosing: 500 mg day 1, then 250 mg daily days 2‑5)【25】.
• TMP‑SMZ is contraindicated at term pregnancy and in nursing mothers【26】.
• Prophylaxis in third‑trimester pregnant women is critical to prevent newborn transmission【25】.

Safety and Contraindications

• Erythromycin carries a dose‑dependent IHPS risk: 5.1 % absolute risk for 8‑14 days of therapy and 10 % for 15‑21 days; risk is highest in infants < 1 month【26】.
• Azithromycin has not been associated with IHPS and is therefore strongly preferred【25】.
• Azithromycin should not be taken concurrently with aluminum‑ or magnesium‑containing antacids because absorption is reduced【25】.
• Erythromycin and clarithromycin inhibit cytochrome P450 enzymes; avoid co‑administration with drugs such as astemizole, cisapride, pimozide, or terfenadine【25】.
• Macrolides are absolutely contraindicated in individuals with a known hypersensitivity to any macrolide【25】.

Infection‑Control Measures

• Home isolation should continue for 5 days after the start of antibiotics; if antibiotics are not given, isolation must extend to 21 days from cough onset【26】.
• In healthcare facilities: place suspected or confirmed cases in private rooms or cohort them with other pertussis patients【26】; wear a surgical mask when within 3 feet of the patient【26】; maintain droplet precautions until 5 days of antimicrobial therapy are completed【26】; symptomatic healthcare workers must be excluded from work for the first 5 days of therapy【26】.

Therapies Without Proven Benefit

• Long‑acting β‑agonists, antihistamines, systemic corticosteroids, and pertussis‑specific immunoglobulin have no demonstrated benefit and should be avoided【25】.

Hospitalization Criteria and Monitoring

• Hospital admission is strongly considered for all infants < 4 months (high risk of apnea, pneumonia, seizures, death)【25】 and for infants < 12 months with severe symptoms【26】.
• Inpatient monitoring should include surveillance for bacterial pneumonia and otitis media【26】 (among other complications).

Key Clinical Pitfalls (CDC Emphasis)

• Do not delay antibiotic therapy while awaiting laboratory confirmation; clinical suspicion alone warrants immediate treatment【25】.
• Do not withhold azithromycin in infants < 6 months despite lack of FDA licensure; CDC recommends its use because benefits outweigh potential risks【25】.
• Do not use erythromycin in infants < 6 months due to the unacceptably high IHPS risk【25】.

Contraindicated Antibiotics in Infants < 2 Months

Trimethoprim‑Sulfamethoxazole (TMP‑SMZ)

• TMP‑SMZ is absolutely contraindicated in infants younger than 2 months because it can cause kernicterus (bilirubin‑induced brain injury). This recommendation is issued by the CDC in its MMWR Recommendations and Reports (2005) and is supported by three separate citations. 27, 28, 29
  Evidence level: not explicitly graded in the source.

• TMP‑SMZ may be used only in children older than 2 months when macrolide antibiotics are contraindicated or not tolerated. This guidance also comes from the CDC’s MMWR Recommendations and Reports (2005). 27
  Evidence level: not explicitly graded in the source.

Clarithromycin

• Clarithromycin should not be given to infants younger than 1 month because its chemical and metabolic similarity to erythromycin raises concerns about a possible association with infantile hypertrophic pyloric stenosis (IHPS), although definitive proof is lacking. This precaution is documented by the CDC in its MMWR Recommendations and Reports (2005) with two supporting citations. 27, 28
  Evidence level: not explicitly graded in the source.

Antibiotic Management of Pertussis (CDC‑MMWR Recommendations)

First‑Line Antibiotic and Age‑Specific Dosing

The CDC strongly recommends azithromycin as the preferred first‑line agent for pertussis in all age groups because of its superior tolerability, short course, and markedly lower risk of infantile hypertrophic pyloric stenosis compared with erythromycin 30.

Alternative Macrolide (Clarithromycin) and When to Use

Clarithromycin is an acceptable alternative when azithromycin cannot be used 30.

Erythromycin (Reserve Use)

Erythromycin should be reserved for situations where macrolides are unavailable; it carries a high risk of IHPS in infants 30.

Trimethoprim‑Sulfamethoxazole (TMP‑SMZ) for Macrolide‑Intolerant or Resistant Cases

When macrolides cannot be used (e.g., allergy, intolerance, or confirmed resistance), TMP‑SMZ for 14 days is the CDC‑recommended alternative 30.

Absolute contraindications: infants < 2 months (risk of kernicterus), pregnant women at term, and nursing mothers. 31

Timing of Treatment and Expected Clinical Benefit

Antibiotics should be started immediately upon clinical suspicion; waiting for laboratory confirmation is not advised 30.

Post‑Exposure Prophylaxis (PEP)

PEP uses the same antimicrobial agents and dosing regimens as treatment 30.

Priority groups (administer within 21 days of exposure):

Definition of close contact: Direct exposure to respiratory secretions during catarrhal or paroxysmal stages (e.g., face‑to‑face within 3 feet, shared confined space) 30.

Infection Control and Isolation

Drug Interactions and Absolute Contraindications